Tamoxifen is a nonsteroidal mixed antiestrogenic agent that is a competitive antagonist at the estrogen receptor [16,17] and has been used to treat breast cancer in postmenopausal women since 1971 [18]. The gene discussed is ESR1; the disease is breast carcinoma.